Furthermore, when comparing the pathological response of reference trastuzumab and Zercepac combined with taxane in treating HER2-positive breast cancer, both reference trastuzumab and Zercepac combined with nab-paclitaxel resulted in higher tpCR rates than did treatment combined with docetaxel alone (69.15% vs. 46.88%, P=0.040; 69.80% vs. 44.44%, P=0.021). This evidence concerns the gene ERBB2 and breast carcinoma.